Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tacrolimus in refractory polymyositis with interstitial lung disease.

Literature DB >> 10347992

Tacrolimus in refractory polymyositis with interstitial lung disease.

C V Oddis, F C Sciurba, K A Elmagd, T E Starzl.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 1999 PMID： 10347992 PMCID： PMC2977932 DOI： 10.1016/S0140-6736(99)01927-3

Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321

× No keyword cloud information.

5 in total

Review 1. Cyclosporine, FK-506, rapamycin, and other immunomodulators.

Authors: D E Yocum
Journal: Rheum Dis Clin North Am Date: 1996-02 Impact factor: 2.670

Review 2. FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh.

Authors: A W Thomson; P B Carroll; J McCauley; J Woo; K Abu-Elmagd; T E Starzl; D H Van Thiel
Journal: Springer Semin Immunopathol Date: 1993

3. Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis.

Authors: E L Arsura; A S Greenberg
Journal: Semin Arthritis Rheum Date: 1988-08 Impact factor: 5.532

4. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups.

Authors: L A Love; R L Leff; D D Fraser; I N Targoff; M Dalakas; P H Plotz; F W Miller
Journal: Medicine (Baltimore) Date: 1991-11 Impact factor: 1.889

5. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy.

Authors: M M Joffe; L A Love; R L Leff; D D Fraser; I N Targoff; J E Hicks; P H Plotz; F W Miller
Journal: Am J Med Date: 1993-04 Impact factor: 4.965

5 in total

48 in total

Tacrolimus in refractory polymyositis with interstitial lung disease.

Review 1. Cyclosporine, FK-506, rapamycin, and other immunomodulators.

Review 2. FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh.

3. Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis.

4. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups.

5. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy.

Review 1. Clinical trials review: idiopathic inflammatory myopathy.

2. Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis.

3. Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

4. Therapeutic advances and future prospects in immune-mediated inflammatory myopathies.

Review 5. Treatment of inflammatory myopathy: emerging therapies and therapeutic targets.

Review 6. [Current treatments of dermatomyositis and polymyositis].

7. Idiopathic inflammatory myopathy: treatment options.

8. Mycophenolate mofetil treatment with or without a calcineurin inhibitor in resistant inflammatory myopathy.

Review 9. Characteristic features of tacrolimus-induced lung disease in rheumatoid arthritis patients.

10. The long-term outcome of anti-Jo-1-positive inflammatory myopathies.